Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAHAL: Hypertonic Saline vs Mannitol for ICP in ALF
NCT02460510Completed
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jun 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Randomised, open-label trial of hypertonic saline in acute liver failure (ALF) and intracranial hypertension (IH) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Response to therapy at 12 hr in reduction of ICP. Started Jun 2014; status: completed.
02
Drugs
hypertonic saline
03
Conditions
acute liver failure (ALF)intracranial hypertension (IH)
Beyond the preview
Go deeper on NCT02460510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460510.